Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $113
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $107 to $113.
June 20, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has maintained its Buy rating on Intra-Cellular Therapies and increased the price target from $107 to $113, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from a reputable analyst firm like Canaccord Genuity suggest positive sentiment and expected growth for Intra-Cellular Therapies. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100